Philogen and The Scripps Research Institute announce research collaboration in the field of DNA-encoded chemistry

Siena, Italy, and La Jolla, California, January 8, 2018 – Philogen S.p.A., a privately-owned company, and The Scripps Research Institute, a nonprofit American medical research facility that focuses on research and education in the biomedical sciences, today announced a research collaboration to discover new small molecule-based therapeutics using Philochem’s proprietary ESAC platform and DNA-Encoded Chemistry technology.

“We are extremely pleased to collaborate with Prof. Richard Lerner, a great scientist and innovator, and The Scripps Research Institute, one of the most innovative leaders in pharmaceutical research and education worldwide. We hope our DNA-Encoded Chemistry technology and ESAC platform will contribute to bring innovative treatments for serious unmet medical needs,” commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.

“It is a privilege to work with the Philogen group,” said Lerner, institute professor and Lita Annenberg Hazen Professor of Immunochemistry at The Scripps Research Institute. “I feel they are one of the intellectual leaders in this field.”

For more information, contact press@scripps.edu See More News